Omnicell Inc. has announced its financial results for the first quarter of 2025, reporting an increase in total revenues to $270 million, up by $24 million or 10% compared to the first quarter of 2024. This growth is attributed to higher revenues from the XT Amplify program and continued expansion in SaaS and Expert Services, with a notable contribution from Specialty Pharmacy Services. The company's GAAP net loss for the first quarter was $7 million, or $0.15 per diluted share, an improvement from a GAAP net loss of $16 million, or $0.34 per diluted share, in the same period of 2024. On a non-GAAP basis, Omnicell reported a net income of $12 million or $0.26 per diluted share, compared to $1 million or $0.03 per diluted share in the first quarter of the prior year. Non-GAAP EBITDA also showed significant improvement, reaching $24 million, up from $11 million in the first quarter of 2024. Omnicell highlighted its focus on driving annual recurring revenue services and mitigating the potential impact of tariffs on its supply chain. The company maintains a strong balance sheet and solid free cash flow, positioning it well to navigate the current macroeconomic environment and continue delivering innovative solutions to its customers.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.